ORPHA:101151
Dystonia 14
Also known as: DYT14
Publications
240
Trials
0
Interventional, condition-specific
Researchers
1,210
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
240 matched papers (150 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
240
240 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
240 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
150 in the last 10 years · low confidence
Phrase hits: 240 · MeSH hits: 0
Who's working on it?
1,210
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Hallett M9 papers · 2021
Human Motor Control Section, NINDS, NIH, Bethesda, Maryland 20892-1428, USA. hallettm@ninds.nih.gov
Papers in Europe PMC - 02Taira T8 papers · 2023
Department of Neurosurgery, Neurological Institute, Tokyo Women's Medical University, Tokyo, Japan.
Papers in Europe PMC - 03Jinnah HA7 papers · 2022
From the Departments of Neurology (S.P.R., A.R.W., A.D.) and Family and Community Medicine (B.S.), University of New Mexico Health Sciences Center, Albuquerque; and Departments of Neurology, Human Genetics, and Pediatrics (H.A.J.), Emory University School of Medicine, Atlanta, GA.
Papers in Europe PMC - 04Tijssen MAJ6 papers · 2025
Department of Neurology University of Groningen, University Medical Centre Groningen Groningen The Netherlands.
Papers in Europe PMC - 05Bhatia KP5 papers · 2023
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology University College London London United Kingdom.
Papers in Europe PMC - 06Horisawa S5 papers · 2023
Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Papers in Europe PMC - 07Kawamata T5 papers · 2023
Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Papers in Europe PMC - 08Klein C4 papers · 2016
Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
Papers in Europe PMC - 09Lohmann K4 papers · 2022
Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
Papers in Europe PMC - 10Albanese A3 papers · 2016
Istituto Clinico Humanitas, Rozzano, Italy; Istituto di Neurologia, Università Cattolica del Sacro Cuore, Milan, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 19 · after dedupe 19 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 19 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (19)
- isrctn·ISRCTN15307328·Recruiting·Leigh syndrome roadmap project: a natural history study (UK)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89285040·Recruiting·A European study of non-progressive ataxia in children
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15571700·No longer recruiting·A trial to test the use of deferiprone in people with neuroferritinopathy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN85338453·No longer recruiting·A study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selnofast in participants with early idiopathic Parkinson's disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17008820·No longer recruiting·Deep brain stimulation in Tourette syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14984258·No longer recruiting·A study to evaluate the safety, tolerability, processing by the body and mechanism of action of multiple doses of ralmitaront with a single dose of risperidone administered to healthy participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN56186994·Suspended·Investigating the possibility and benefit of closed-loop deep brain stimulation by detecting the voluntary movement and postural tremor on patients with tremor
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13759640·Stopped·High-frequency deep brain stimulation in the treatment of movement disorders
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN69044459·No longer recruiting·Exercise therapy intervention for children and young adults with cerebral palsy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN32597955·No longer recruiting·Retrospective study on the evaluation of chronic and long-term pain therapeutics to manage post-traumatic cervical dystonia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46828292·No longer recruiting·Treatment of complex regional pain syndrome (CRPS) with sensory-motor adaptation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57997252·No longer recruiting·Does the use of a specific cognitive intervention for children with movement disorders improve functional outcomes following deep brain stimulation?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36604066·No longer recruiting·Neuroimaging the effects of modafinil in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66900787·No longer recruiting·Neuroimaging effects of a single dose of modafinil on brain activation in patients with schizophrenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN58484608·No longer recruiting·Constraint induced movement therapy: A randomised controlled Trial in Children with Hemiplegic cerebral palsy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN50622732·No longer recruiting·Pharmacodynamics/electroencephalographic (EEG) study with Ginkgo biloba special extract EGb 761®
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN97049967·No longer recruiting·Phase 3 long-term safety, tolerability and effectiveness of lurasidone in subjects with schizophrenia or schizoaffective disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN01838427·No longer recruiting·The effect of intrathecal methylprednisolone on features of central sensitisation in patients with chronic complex regional pain syndrome (CRPS) type one
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN75413193·No longer recruiting·Double-blind randomised placebo-controlled cross-over study to investigate the safety and effectiveness of intrathecal glycine on pain and dystonia in Complex Regional Pain Syndrome type 1
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Dystonia 14 — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Dystonia 14" OR "DYT14"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Dystonia 14" OR "DYT14"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low
Ingested 2026-07-27T07:21:17.015Z
